European Union & Sanofi
11 shared events · Importance 3 · Last updated Aug 21, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
European Union: The primary target of the open letter, which asks the bloc and its member states to boost pharmaceutical investment, speed up trials and provide fiscal flexibility on healthcare spending. How the European Union responds could shape the region's drug industry competitiveness.
Sanofi: A signatory of the open letter calling on the European Union to boost pharmaceutical investment. The appeal reflects its concern about Europe lagging the United States and China in drug research and trials.
Sep 22, 2026 · 6 articles
Business
European Union: Venglustat is also under regulatory review in the European Union, indicating potential future market expansion for Sanofi.
Sanofi: Sanofi has received priority review for its drug venglustat, which could significantly expand its portfolio in lysosomal storage diseases and provide a new revenue stream if approved.
May 28, 2026 · 6 articles
International
European Union: The EU stands to benefit from closer Vietnam-France ties and progress on the EU-Vietnam Investment Protection Agreement.
Sanofi: Sanofi is involved in a planned large-scale vaccine production project with Vietnam Vaccine Joint Stock Company in Ho Chi Minh City, which could expand its market presence in Vietnam.
Sep 05, 2026 · 12 articles
Regulatory
European Union: EU patent for Aqueol is in final approval stages, which could open a major market for Pulse.
Sanofi: Already a customer of Pulse's manufacturing, the approval may strengthen their supply relationship.
Aug 20, 2026 · 6 articles
Regulatory
European Union: The EU is reviewing mFLUSIVA, which could expand Moderna's market access.
Sanofi: Sanofi's high-dose flu vaccine served as a comparator in trials; the new mRNA vaccine may compete with its products.
Aug 05, 2026 · 105 articles
Business
European Union: The EU approved Awiqli, supporting its international availability.
Sanofi: Sanofi's Lantus faces new competition from Awiqli, which offers less frequent dosing and lower cost per unit.
Jul 09, 2026 · 21 articles
Business
European Union: The European Union is another major market where Tezspire is already approved for severe asthma. Positive trial results may support regulatory approval for eosinophilic esophagitis.
Sanofi: Sanofi's Dupixent competes with Tezspire in severe asthma and potentially in eosinophilic esophagitis. Tezspire's success could increase competitive pressure on Dupixent.
Aug 27, 2026 · 6 articles
Regulatory
European Union: The EU is one of the regions where QDENGA has received regulatory approval, indicating its acceptance in developed markets.
Sanofi: Sanofi's dengue vaccine Dengvaxia is not approved in India and is only recommended for those with prior infection, contrasting with QDENGA's broader indication.
Jul 20, 2026 · 93 articles
Business
European Union: Regulatory jurisdiction where EMA PRIME designation and Orphan Drug designation were granted.
Sanofi: Mentioned as a collaborator with Innate, not directly involved in this partnership.
Aug 10, 2026 · 10 articles
Business
Sanofi: Sanofi, in collaboration with Regeneron Pharmaceuticals, developed Dupixent and received International — European Commission approval for its use in treating chronic spontaneous urticaria in young children, which is expected to boost its market position and revenue.
Apr 13, 2026 · 8 articles
70
Sanofi signed open letter European UnionEuropean Drugmakers Urge...
ERGEN INTELLIGENCE
Explore this relationship live
Track how European Union and Sanofi interact across events, view sentiment trends, and discover connected entities.
Open Dashboard